Cel therapy
Overcoming limitations of traditional assay enables definitive diagnosis, refinement of prognosis and opportunities for optimized treatment Excerpt from the Press Release: CARLSBAD, Calif.–(BUSINESS WIRE)–Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced the publication of a study from investigators at Johns Hopkins University showing…
First patient received bilateral administration of NRTX-1001; no significant surgical complications or adverse events reported to date Trial funded by a $14 million grant from California Institute for Regenerative Medicine Data from this bilateral trial, together with results from the previously announced Phase 3 EPIC study in unilateral MTLE, are intended to support a future…
Excerpt from the Press Release: WATERTOWN, Mass., May 15, 2025 /PRNewswire/ — Orna Therapeutics, a leading biotechnology company developing a proprietary pipeline of in vivo therapies across a broad range of autoimmune and oncology indications, today announced the presentation of new preclinical data supporting its in vivo CAR therapy approach in autoimmune diseases during an…
I Peace, in Cooperation with SBI Holdings, Unveils Next-Gen Cell Mass-Manufacturing System “EGG” at SBI Holdings Inc. booth in the Osaka Healthcare Pavilion “Nest for Reborn” at the 2025 World Expo, Osaka Excerpt from the Press Release: PALO ALTO, Calif. , April 24, 2025 /PRNewswire/ — I Peace, Inc. (https://ipeace.com/en/), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived…
Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomized Trial Excerpt from the Press Release: SUNNYVALE, Calif., April 25, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced completion of enrollment and collection of the…
Misetionamide showed broad antineoplastic activity in 15 different cancer types including multiple human cancer cell lines with no detrimental effect on normal cells Misetionamide reduces energy metabolism by inhibiting aerobic glycolysis Excerpt from the Press Release: BERWYN, PA, Feb. 01, 2024 (GLOBE NEWSWIRE) — Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company…
Excerpt from the Press Release: SAN FRANCISCO, USA – February 1, 2024 – Mahana Therapeutics, a leading provider of digital therapeutics, announced today that positive results from a large US-based Pilot Clinical Trial, have been accepted for presentation at the upcoming American Audiology Society (AAS) Scientific and Technology Meeting, on February 15-17, 2024 in Scottsdale,…
Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Xcell Biosciences, Inc. (Xcellbio), a platform technology company focused on cell and gene therapy applications, today announced a collaboration with ElevateBio, LLC (ElevateBio), through which the companies aim to explore novel approaches to improving therapeutic potency of cell and gene therapies. As part of this collaboration, ElevateBio becomes…
Phase 1 study aims to evaluate safety and tolerability of a single ascending dose of RCT1100 in patients with PCD caused by mutations in the DNAI1 gene RCT1100 is the first clinical evaluation of an inhaled mRNA-based therapy designed to restore ciliary function in people with PCD Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS…
Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation (“Immusoft”), a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, today announced the first patient dosed with engineered B cell therapy ISP-001 in a Phase 1 trial in MPS I, at M…